Prevention of corneal allograft rejection in a mouse model of high risk recipients

British Journal of Ophthalmology

Volumn 88, Issue 10, 2004, Pages 1338-1342

  Vitova A ^a,b   Filipec, M ^b   Zajicova A ^a   Krulova M ^a,b   Holan V ^a,b  

^a INSTITUTE OF MOLECULAR GENETICS   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY THY 1.2; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 8; UNCLASSIFIED DRUG;

ALLOTRANSPLANTATION; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; CORNEA TRANSPLANTATION; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; MALE; MOUSE; NONHUMAN; PENETRATING KERATOPLASTY; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOSPORINE; DISEASE MODELS, ANIMAL; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KERATOPLASTY, PENETRATING; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYCOPHENOLIC ACID; POSTOPERATIVE CARE;

EID: 4744357511     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2003.039388     Document Type: Article

References (37)

1. Williams KA, Muehlberg SM, Lewis RF, et al. The Australian corneal graft registry 1996 report. Adelaide: Mercury Press, 1997;11:47-50.
2. Williams KA, Muehlberg SM, Lewis RF, et al. Long-term outcome in corneal allotransplantation. Transplant Proc 1997;29:983.
3. Kuffová L, Holán V, Lumsden L, et al. Cell subpopulations in failed human corneal grafts. Br J Ophthalmol 1999;83:1364-9.
4. Larkin DF, Alexander RA, Cree IA. Infiltrating inflammatory cell phenotypes and apoptosis in rejected human corneal allografts. Eye 1997;11:68-74.
5. Kuffova L, Lumsden L, Veselá V, et al. Kinetics of leukocyte and myeloid cell traffic in the murine corneal allograft response. Transplantation 2001;72:1292-8.
6. Larkin DF, Colder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection. Clin Exp Immunol 1997;107:381-91.
7. Veen GV, Broersma L, Dijkstra CD, et al. Prevention of corneal allograft rejection in rats treated with subconjunctival injections of liposomes containing dichloromethylene diphosphonate. Invest Ophthalmol Vis Sci 1994;35:3505-15.
8. Krulová M, Zajícová A, Frič J, et al. Alloantigen-induced, T-cell-dependent production of nitric oxide by macrophages infiltrating skin allografts in mice. Transplant Int 2002;15:108-16.
9. Ayliffe W, Alam Y, Bell EB, et al. Prolongation of rat corneal graft survival by treatment with anti-CD4 monoclonal antibody. Br J Ophthalmol 1992;76:602-6.
10. He YG, Ross J, Niederkorn JY. Promotion of murine orthotopic corneal allograft survival by systemic administration of anti-CD4 monoclonal antibody. Invest Ophthalmol Vis Sci 1991;32:2723-8.
11. Thiel MA, Takano T, Hawksworth N, et al. Low-dose, short-term treatment with anti-CD4 monoclonal antibody prolongs corneal allograft survival. Transplant Proc 2001;33:635-6.
12. Pleyer U, Milani JK, Dukes A, et al. Effect of topically applied anti-CD4 monoclonal antibodies on orthotopic corneal allografts in a rat model. Invest Ophthalmol Vis Sci 1995;36:52-61.
13. Ippoliti G, Fronterre A. Use of locally injected anti-T monoclonal antibodies in me treatment of acute corneal graft rejection. Transplant Proc 1987;19:2579-80.
14. Ippoliti G, Fronterre A. Usefulness of CD3 or CD6 anti-T monoclonal antibodies in the treatment of acute corneal graft rejection. Transplant Proc 1989;21:3133-4.
15. Newman DK, Isaacs JD, Watson PG, et al. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, Campath-1H. Eye 1995;9:564-9.
16. Dick AD, Meyer P, James T, et al. Campath-1H therapy in refractory ocular inflammatory disease. Br J Ophthalmol 2000;84:107-9.
17. Schmitz K, Hitzer S, Behrens-Baumann W. Immune suppression by combination therapy with basiliximab and cyclosporin in high risk keratoplasty. A pilot study. Ophthalmology 2002;99:38-45.
18. Reis A, Reinhard T, Voiculescu A, et al. Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: prospectively randomised clinical trial. Br J Ophthalmol 1999;83:1268-71.
19. Reinhard T, Reis A, Bohringer D, et al. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial. Graefes Arch Clin Exp Ophthalmol 2001;239:367-72.
20. Soares-Wulf A, Aboalchamat B, Krüger R, et al. Long-term results of immunosuppressive therapy with mycophenolate mofetil (CellCept) for keratoplasty in high-risk patients. Invest Ophthalmol Vis Sci 2002;43:E-Abstract 2241.
21. Poon AC, Forbes JE, Dart JKG, et al. Systemic cyclosporin A in high risk penetrating keratoplasties: a case-control study. Br J Ophthalmol 2001;85:1464-9.
22. She SC, Steahly LP, Moticka EJ. A method for performing full-thickness, orthotopic, penetrating keratoplasty in the mouse. Ophthalmic Surg 1990;21:781-5.
23. Plšková J, Duncan L, Holáň V, et al. The immune response to corneal allograft requires a site-specific draining lymph node. Transplantation 2002;73:210-15.
24. Plšková J, Kuffová L, Holáň V, et al. Evaluation of corneal graft rejection in a mouse model. Br J Ophthalmol 2002;86:108-13.
25. Lake P, Clark EA, Khorshidi M, et al. Production and characterization of cytotoxic Thy-1 antibody-secreting hybrid cell lines. Detection of T cell subsets. Eur J Immunol 1979;9:875-86.
26. Dialynas DP, Wilde DB, Marrack P, et al. Characterization of the murine antigenic determinant designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T-cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol Rev 1983;74:29-56.
27. Gottlieb PD, Marshak-Rothstein A, Auditore-Hargreaves K, et al. Construction and properties of new Lyt-congeneic strains and anti-Lyt-2.2 and anti-Lyt-3.1 monoclonal antibodies. Immunogenetics 1980;10:545-52.
28. Reis A, Reinhard T, Sundmacher R, et al. Effect of mycophenolate mofetil, cyclosporin A, and both in combination in a murine corneal graft rejection model. Br J Ophthalmol 1998;82:700-3.
29. Reis A, Megahed M, Reinhard T, et al. Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation. Transplantation 2000;70:1397-407.
30. Shepherd WF, Coster DJ, Fook TC, et al. Effect of cyclosporine A on the survival of corneal grafts in rabbits. Br J Ophthalmol 1980;64:148-53.
31. Coster DJ, Shepard WFI, Chin Fook T, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporine A. Lancet 1979;2:688-9.
32. Hill JC, Maske R. An animal model for corneal graft rejection in high risk keratoplasty. Transplantation 1988;46:26-30.
33. Rehany U, Waisman M. Suppression of corneal allogtaft rejection by systemic cyclosporine-A in heavily vascularized rabbit corneas following alkali burns. Cornea 1994;13:447-53.
34. + T cells in immunobiology of orthotopic corneal transplants in mice. Invest Ophthalmol Vis Sci 1999;40:2614-21.
35. + T cells in allorecognition: Lessons from corneal transplantation. J Immunol 2001;167:1891-9.
36. Hedge S, Niederkorn JY. The role of cytotoxic T lymphocytes in corneal allograft rejection. Invest Ophthalmol Vis Sci 2000;41:3341-7.
37. Yamada J, Ksander BR, Streilein JW. Cytotoxic T cells play no essential role in acute rejection of orthotopic corneal allografts in mice. Invest Ophthalmol Vis Sci 2001;42:386-92.